PTC Therapeutics, Inc.

The current price of PTCT is $65.67 — it has decreased by 4.78% since the previous close. Data as of Nov 5, 2026.

PTCT is up 1.42% over the past week, up 3.17% over the past month and down 8.50% over the past year. The price is below its 200-day moving average of $70.56.

Analysts' average 12-month price target for PTCT is $102.89, which implies 56.68% upside from the current price. Individual estimates range from $75.00 to $137.00.

In its most recent quarterly report, PTC Therapeutics, Inc. posted a loss of $0.62 per share against an estimate of $0.1434, missing expectations by 532.36%. Upcoming reports are listed in the earnings calendar.

PTC Therapeutics, Inc. reported revenue of $357.81M in its most recent quarter, which has increased by 69.57% compared with the same quarter a year earlier. Analysts had expected $306.43M.

Companies most comparable to PTC Therapeutics, Inc. include BridgeBio Pharma, Inc., BioMarin Pharmaceutical Inc., Krystal Biotech, Inc., Ionis Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.

In the latest trading session PTCT moved between $65.47 and $69.59, a range of 6.27% of its current price.

Over the past 52 weeks PTCT has traded between $58.80 and $90.87. The current price is 27.73% below its 52-week high.